$ARVN
Arvinas Inc
PRICE
$22.79 -
Extented Hours
VOLUME
212,347
DAY RANGE
22.56 - 23.23
52 WEEK
22 - 58.58
Key Metrics
Market Cap
1.22 B
Beta
1.59
Avg. Volume
411.14 K
Shares Outstanding
53.40 M
Yield
0%
Public Float
0
Next Earnings Date
2023-08-03
Next Dividend Date
Company Information
Arvinas is a clinical-stage biopharmaceutical company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. Arvinas uses its proprietary PROTAC® Discovery Engine platform to engineer proteolysis targeting chimeras, or PROTAC® targeted protein degraders, that are designed to harness the body's own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. In addition to its robust preclinical pipeline of PROTAC® protein degraders against validated and "undruggable" targets, the company has two clinical-stage programs: ARV-110 for the treatment of men with metastatic castrate-resistant prostate cancer; and ARV-471 for the treatment of patients with locally advanced or metastatic ER+/HER2- breast cancer.
CEO: John G. Houston
Website: arvinas.com
HQ: 5 Science Park 395 Winchester Ave New Haven, 06511 CT
Related News